Gene therapy for Wiskott-Aldrich Syndrome—Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis

References

• Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in wiskott-aldrich syndrome. Cell 1994; 78:635-44; PMID:8069912; http://dx.doi.org/10.1016/0092-8674(94)90528-2
   PubMed Web of Science ®Google Scholar
• Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol. Blood Marrow Transpl 2009; 15:84-90; PMID:19147084; http://dx.doi.org/10.1016/j.bbmt.2008.10.007
   PubMed Web of Science ®Google Scholar
• Thrasher AJ. Wasp in immune-system organization and function. Nat Rev Immunol 2002; 2:635-46; PMID:12209132; http://dx.doi.org/10.1038/nri884
   PubMed Web of Science ®Google Scholar
• Bouma G, Burns SO, Thrasher AJ. Wiskott–aldrich syndrome: immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology 2009; 214:778-90.
   PubMed Web of Science ®Google Scholar
• Banerjee PP, Pandey R, Zheng R, Suhoski MM, Monaco-Shawver L, Orange JS. Cdc42-interacting protein-4 functionally links actin and microtubule networks at the cytolytic NK cell immunological synapse. J Exp Med 2007; 204:2305-20; PMID: 17785506; http://dx.doi.org/10.1084/jem.20061893
   PubMed Web of Science ®Google Scholar
• Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, Yata J-I, Mizutani S, Ochs HD, Nonoyama S, Clinical course of patients with WASP gene mutations. Blood 2004; 103:456-64; PMID:12969986; http://dx.doi.org/10.1182/blood-2003-05-1480
   PubMed Web of Science ®Google Scholar
• Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, Cant AJ, Thrasher AJ, Cowan MJ, Albert MH, et al. Long-term outcome and lineage-specific chimerism in 194 patients with wiskott-aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118:1675-84; PMID:21659547; http://dx.doi.org/10.1182/blood-2010-11-319376
   PubMed Web of Science ®Google Scholar
• Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011; 12:316-28; PMID:21468099; http://dx.doi.org/10.1038/nrg2971
   PubMed Web of Science ®Google Scholar
• Fischer A, Hacein-Bey Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010; 11:457-60; PMID:20485269; http://dx.doi.org/10.1038/ni0610-457
   PubMed Web of Science ®Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-9; PMID: 16582916; http://dx.doi.org/10.1038/nm1393
   PubMed Web of Science ®Google Scholar
• Aiuti A. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-3; PMID:12089448; http://dx.doi.org/10.1126/science.1070104
   PubMed Web of Science ®Google Scholar
• Aiuti A, Cattaneo F, Galimberti S. Gene therapy for immunodeficiency due to adenosine deaminase deficiency – NEJM, … Engl J 2009; 360:447-58.
   Web of Science ®Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669-72; PMID:10784449; http://dx.doi.org/10.1126/science.288.5466.669
   PubMed Web of Science ®Google Scholar
• Hacein-Bey Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay J-P, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, et al. Sustained correction of X-Linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-93; PMID:11961146; http://dx.doi.org/10.1056/NEJMoa012616
   PubMed Web of Science ®Google Scholar
• Hacein-Bey Abina S, Hauer J, Lim A, Picard C., Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, et al. Efficacy of gene therapy for X-Linked severe combined immunodeficiency. N Engl J Med 2010; 363:355-64; PMID: 20660403; http://dx.doi.org/10.1056/NEJMoa1000164
   PubMed Web of Science ®Google Scholar
• Dave UP. Gene therapy insertional mutagenesis insights. Science 2004; 303:333; PMID:14726584; http://dx.doi.org/10.1126/science.1091667
   PubMed Web of Science ®Google Scholar
• Hacein-Bey Abina S, Garrigue A, Wang G P, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118:3132-42; PMID:18688285; http://dx.doi.org/10.1172/JCI35700
   PubMed Web of Science ®Google Scholar
• Hacein-Bey Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval J-L, Fraser CC, Cavazzana-Calvo M, et al. Adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-6; PMID:12529469; http://dx.doi.org/10.1056/NEJM200301163480314
   PubMed Web of Science ®Google Scholar
• Hacein-Bey Abina S, Von Kalle C, Schmidt M, McCormack M P, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-9; PMID:14564000; http://dx.doi.org/10.1126/science.1088547
   PubMed Web of Science ®Google Scholar
• Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118:3143-50; PMID:18688286; http://dx.doi.org/10.1172/JCI35798
   PubMed Web of Science ®Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-9; PMID: 16582916; http://dx.doi.org/10.1038/nm1393
   PubMed Web of Science ®Google Scholar
• Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198-204; 1-8; PMID:20057388
   PubMed Web of Science ®Google Scholar
• Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363:1918-27; PMID:21067383; http://dx.doi.org/10.1056/NEJMoa1003548
   PubMed Web of Science ®Google Scholar
• Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, Modlich U, Beier R, Göhring G, Steinemann D, et al. Gene therapy for wiskott-aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med 2014; 6:227ra33; PMID: 24622513; http://dx.doi.org/10.1126/scitranslmed.3007280
   PubMed Web of Science ®Google Scholar
• Thrasher AJ, Hacein-Bey Abina S, Gaspar HB, Blanche S, Davies EG, Parsley K, Gilmour K, King D, Howe S, Sinclair J, et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005; 105:4255-7; PMID:15687233; http://dx.doi.org/10.1182/blood-2004-12-4837
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, Pilz I, Braun S, Glimm H, von Kalle C. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007; 4:1051-7; PMID:18049469; http://dx.doi.org/10.1038/nmeth1103
   PubMed Web of Science ®Google Scholar
• Ho PA, Alonzo TA, Gerbing RB, Pollard J A, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. Br J Haematol 2013; 162:670-7; PMID:23826732; http://dx.doi.org/10.1111/bjh.12444
   PubMed Web of Science ®Google Scholar
• Nam C-H, Rabbitts TH. The Role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol Ther 2006; 13:15-25; PMID:16260184; http://dx.doi.org/10.1016/j.ymthe.2005.09.010
   PubMed Web of Science ®Google Scholar
• Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17:1919-28; PMID:19672245; http://dx.doi.org/10.1038/mt.2009.179
   PubMed Web of Science ®Google Scholar
• Wu XL, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300:1749-51; PMID:12805549; http://dx.doi.org/10.1126/science.1083413
   PubMed Web of Science ®Google Scholar
• Muñoz P, Toscano MG, Real PJ, Benabdellah K, Cobo M, Bueno C, Ramos-Mejı´a V, Menendez P, Anderson P, Martı´n F, Specific marking of hESCs-derived hematopoietic lineage by WAS-Promoter driven lentiviral vectors. PLoS ONE 2012; 7:e39091; PMID: 22720040; http://dx.doi.org/10.1371/journal.pone.0039091
   PubMed Web of Science ®Google Scholar
• Toscano MG, Romero Z, Muñoz P, Cobo M, Benabdellah K, Martin F. Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Ther 2011; 18:117-27.
   Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341: 1233151.
   Web of Science ®Google Scholar
• Engelstädter M, Buchholz CJ, Bobkova M, Steidl S, Merget-Millitzer H, Willemsen RA, Stitz J, Cichutek K. Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins. Gene Ther 2001; 8:1202-6; http://dx.doi.org/10.1038/sj.gt.3301500
   PubMed Web of Science ®Google Scholar
• Funke S, Maisner A, hlebach MDMU, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ. Targeted cell entry of lentiviral vectors. Mol Ther 2008; 16:1427-36; PMID:18578012; http://dx.doi.org/10.1038/mt.2008.128
   PubMed Web of Science ®Google Scholar
• Baum C, von Kalle C, Staal FJT, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA. Chance or necessity? insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004; 9:5-13; PMID:14741772; http://dx.doi.org/10.1016/j.ymthe.2003.10.013
   PubMed Web of Science ®Google Scholar
• Anderson WF. The best of times, the worst of times. Science 2000; 288:627-9; PMID:10799000; http://dx.doi.org/10.1126/science.288.5466.627
   PubMed Web of Science ®Google Scholar
• Haigis KM. A. sweet-cordero, new insights into oncogenic stress. Nat Genet 2011; 43:177-8; PMID: 21350495; http://dx.doi.org/10.1038/ng0311-177
   PubMed Web of Science ®Google Scholar
• Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev 2012; 12.
   Google Scholar
• Dewey RA, Avedillo Dı´ez I, Ballmaier M, Filipovich A, Greil J, Güngör T, Happel C, Maschan A, Noyan F, Pannicke U, et al. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. Exp Hematol 2006; 34:1161-9; PMID: 16939809; http://dx.doi.org/10.1016/j.exphem.2006.04.021
   PubMed Web of Science ®Google Scholar